According to multiple reports, Eli Lilly has held preliminary discussions with French government officials regarding a potential takeover of Abivax, a Montpellier-based biotech firm. Abivax’s lead asset, obefazimod, is in two positive phase 3 ulcerative colitis trials, delivering remission rates significantly above placebo in patients who previously failed standard therapies. Abivax’s market capitalization recently surged to €9.5 billion, reflecting investor enthusiasm for obefazimod’s novel mechanism of action and potential extension into other immunology indications.

The deal would represent one of Lilly’s largest acquisitions to date and underscores its strategy of bolstering the immunology pipeline beyond its GLP-1 leadership. By acquiring obefazimod, Lilly could gain immediate late-stage exposure in a $7 billion global ulcerative colitis market, complementing existing products such as Taltz and Olumiant. Analysts estimate that if obefazimod achieves approval and launches in 2028, it could reach peak annual sales of $2 billion, helping offset eventual attrition in Lilly’s diabetes and weight-loss franchises.

This potential transaction highlights Lilly’s broader effort to reduce reliance on its flagship GLP-1 therapies. Over the past two years, the company has completed three acquisitions totaling over $10 billion, expanding into oncology and pain management. Adding obefazimod would further diversify its portfolio, positioning Lilly to compete across multiple high-growth immunology segments. Investors will closely monitor any announced deal terms and integration plans, as successful execution will be critical to preserving Lilly’s credit metrics and dividend growth profile.